Cancer
Malignant Central Nervous System Neoplasm
CI-CAN-00001115Explore in graph →
Top-level822 active trials5 approved drugs103 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00001115Explore in graph →
Clinical trials
2,864 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (418)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04845139 | A Case Study of Nivolumab for Relapsed/Refractory Primary Central Nervous System Lymphoma | unknown | N/A | 1 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Jul 7, 2022 | clinicaltrials |
| NCT05099068 | Profiling Program of Cancer Patients With Sequential Tumor and Liquid Biopsies (PLANET)(PLANET) | unknown | N/A | 500 | Centre Leon BerardOTHER | 1 | Jul 5, 2022 |
| clinicaltrials |
| NCT05425654 | RL-MPV Followed by BBC HCT Using Autologous Stem Cells and Maintenance Therapy With Nivolumab for Newly Diagnosed PCNSL | unknown | Phase 2 | 30 | National Research Center for Hematology, RussiaNETWORK | 1 | Jun 21, 2022 | clinicaltrials |
| NCT03243461 | International Cooperative Phase III Trial of the HIT-HGG Study Group (HIT-HGG-2013)(HIT-HGG-2013) | unknown | Phase 3 | 167 | University of GöttingenOTHER | 1 | Jun 6, 2022 | clinicaltrials |
| NCT04831658 | A Prospective Clinical Study of BTK Inhibitor, PD-1 and Formustine in the First-line Treatment of Primary Central Nervous System Lymphoma | unknown | Phase 1 / Phase 2 | 40 | Mingzhi ZhangOTHER | 1 | Jun 2, 2022 | clinicaltrials |
| NCT05028270 | Treatment of Intraocular Retinoblastoma | unknown | — | 1,600 | Xinhua Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 0 | Jun 1, 2022 | clinicaltrials |
| NCT05399524 | Functional and Ultrasound Guided Resection of Glioblastoma(FUTURE-GB) | unknown | N/A | 357 | University of OxfordOTHER | 1 | Jun 1, 2022 | clinicaltrials |
| NCT05398224 | R-MTX-zanbrutinib in Secondary CNS Lymphoma | unknown | Phase 2 | 45 | Peking UniversityOTHER | 1 | May 31, 2022 | clinicaltrials |
| NCT04501731 | Controlling Coordination After Childhood Cerebellar Cancer, a Pilot Study(5C-pilot) | unknown | — | 10 | University of NottinghamOTHER | 1 | May 25, 2022 | clinicaltrials |
| NCT05390749 | Sequential Treatment With RO-MTX After Pomalidomide, Orelabrutinib, Rituximab (POR) in Newly-diagnosed PCNSL | unknown | Phase 2 | 50 | Peking Union Medical College HospitalOTHER | 1 | May 25, 2022 | clinicaltrials |
| NCT05385185 | Clinical Observation of ICI Combined With Recombinant Human Endostatin on Leptomeningeal Metastasis of Lung Cancer | unknown | Phase 2 | 20 | Hebei Medical UniversityOTHER | 1 | May 23, 2022 | clinicaltrials |
| NCT00045968 | Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer(GBM) | unknown | Phase 3 | 348 | Northwest BiotherapeuticsINDUSTRY | 4 | May 18, 2022 | clinicaltrials |
| NCT05366062 | ERC1671 to Treat Malignant Gliomas When Given in Combination With GM-CSF, Cyclophosphamide, Bevacizumab and Pembrolizumab | unknown | Phase 2 | 28 | Epitopoietic Research CorporationINDUSTRY | 1 | May 13, 2022 | clinicaltrials |
| NCT02623010 | Bruton's Tyrosine Kinase Inhibitor Ibrutinib as Maintenance Treatment in Elderly Patients With Primary CNS Lymphoma | unknown | Phase 2 | 30 | Rabin Medical CenterOTHER | 1 | May 10, 2022 | clinicaltrials |
| NCT00075387 | Combination Chemotherapy With or Without Sodium Thiosulfate in Preventing Low Platelet Count While Treating Patients With Malignant Brain Tumors | unknown | Phase 2 | 48 | OHSU Knight Cancer InstituteOTHER | 1 | May 3, 2022 | clinicaltrials |
| NCT05333588 | The Safety Study of Autologous TILs Therapy for Patients With Glioblastoma Multiforme. | unknown | Early Phase 1 | 20 | Hebei Senlang Biotechnology Inc., Ltd.INDUSTRY | 1 | Apr 19, 2022 | clinicaltrials |
| NCT05334238 | Orelabrutinib Maintenance Therapy After ASCT in Primary Central Nervous System Lymphoma | unknown | Phase 3 | 174 | Ruijin HospitalOTHER | 1 | Apr 19, 2022 | clinicaltrials |
| NCT02973256 | Oncological Care for Patients With Meningioma(ATYPICMENING) | unknown | — | 1,204 | University Hospital, MontpellierOTHER | 1 | Apr 14, 2022 | clinicaltrials |
| NCT04514393 | Ibrutinib With Methotrexate and Temozolomide for Patients With Newly Diagnosed Primary CNS Lymphoma | unknown | Phase 2 | 33 | Huiqiang HuangOTHER | 1 | Apr 7, 2022 | clinicaltrials |
| NCT05308043 | Deep Learning in Retinoblastoma Detection and Monitoring. | unknown | — | 200 | Beijing Tongren HospitalOTHER | 1 | Apr 1, 2022 | clinicaltrials |
| NCT02313389 | Maintenance Treatment Versus Observation in Elderly Patients With PCNS Lymphoma(BLOCAGE-01) | unknown | Phase 3 | 428 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Mar 2, 2022 | clinicaltrials |
| NCT04253496 | Mathematic Modeling at Micro and Macroscopic Level of Primary Central Nervous System Lymphomas (PCNSL)(LOC-MODEL) | unknown | — | 100 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Feb 18, 2022 | clinicaltrials |
| NCT02796261 | Study to Evaluate Eflornithine + Lomustine vs Lomustine in Recurrent Anaplastic Astrocytoma (AA) Patients(STELLAR) | unknown | Phase 3 | 343 | Orbus Therapeutics, Inc.INDUSTRY | 8 | Jan 21, 2022 | clinicaltrials |
| NCT05201326 | Irinotecan And Bevacizumab Combined With Re-radiotherapy in Recurrent Glioblastoma | unknown | Phase 1 | 20 | Ruijin HospitalOTHER | 1 | Jan 21, 2022 | clinicaltrials |
| NCT05167630 | Prognosis Factors in Patients With Primary Central Nervous System Lymphoma | unknown | — | 40 | Zhengzhou UniversityOTHER | 1 | Dec 22, 2021 | clinicaltrials |
| NCT03400917 | Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens for Treatment of Newly Diagnosed Glioblastoma | unknown | Phase 2 | 55 | Aivita Biomedical, Inc.INDUSTRY | 1 | Dec 16, 2021 | clinicaltrials |
| NCT04888611 | Neoadjuvant PD-1 Antibody Alone or Combined With DC Vaccines for Recurrent Glioblastoma | unknown | Phase 2 | 40 | Huashan HospitalOTHER | 1 | Nov 30, 2021 | clinicaltrials |
| NCT05131711 | Combination of Stereotactic Radiosurgery and Enhanced Immunotherapy for Recurrent Glioblastomas(inSituVac2)(CSREIG)(CSREIG) | unknown | Phase 1 / Phase 2 | 60 | Beijing Tiantan HospitalOTHER | 1 | Nov 23, 2021 | clinicaltrials |
| NCT05131763 | NKG2D-based CAR T-cells Immunotherapy for Patient With r/r NKG2DL+ Solid Tumors | unknown | Phase 1 | 3 | Fudan UniversityOTHER | 1 | Nov 23, 2021 | clinicaltrials |
| NCT05108012 | Nk Cell Therapy for Recurrent Glioblastoma Multiform Patients | unknown | Phase 1 | 5 | Royan InstituteOTHER_GOV | 1 | Nov 22, 2021 | clinicaltrials |
| NCT05125666 | Efficacy of Dual Task Training on Children With Ataxia After Medulloblastoma Resection | unknown | Phase 2 | 30 | Cairo UniversityOTHER | 1 | Nov 18, 2021 | clinicaltrials |
| NCT00983398 | Melphalan, Carboplatin, Mannitol, and Sodium Thiosulfate in Treating Patients With Recurrent or Progressive CNS Embryonal or Germ Cell Tumors | unknown | Phase 1 / Phase 2 | 17 | OHSU Knight Cancer InstituteOTHER | 1 | Oct 26, 2021 | clinicaltrials |
| NCT05054426 | Intermediate Dose of IV MTX as CNS Prophylaxis for High Risk DLBCL(NHL-011) | unknown | Phase 3 | 488 | Peking Union Medical College HospitalOTHER | 1 | Sep 23, 2021 | clinicaltrials |
| NCT00293475 | Methotrexate, Mannitol, Rituximab, and Carboplatin in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma | unknown | Phase 1 / Phase 2 | 81 | OHSU Knight Cancer InstituteOTHER | 1 | Sep 22, 2021 | clinicaltrials |
| NCT03582254 | Role of [18F]-FDG Brain PET in Newly Diagnosed Primary Cerebral Lymphoma, in Immunocompetent Patient Older Than 60 Years(LOCALYSE) | unknown | N/A | 62 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Sep 10, 2021 | clinicaltrials |
| NCT05033587 | Study of AK105 With Anlotinib and Radiotherapy Adjuvant Therapy in MGMT Unmethylated Newly Diagnosed Glioblastoma. | unknown | Phase 2 | 28 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Sep 5, 2021 | clinicaltrials |
| NCT05021770 | Orelabrutinib in Combination With Thiotepa in Refractory and Relapsed Primary CNS Lymphoma | unknown | Phase 1 / Phase 2 | 29 | Huiqiang HuangOTHER | 1 | Aug 26, 2021 | clinicaltrials |
| NCT03347097 | Adoptive Cell Therapy of Autologous TIL and PD1-TIL Cells for Patients With Glioblastoma Multiforme | unknown | Early Phase 1 | 40 | Huashan HospitalOTHER | 1 | Aug 25, 2021 | clinicaltrials |
| NCT04728568 | Exploratory Study of PD-1 Neoadjuvant Treatment of Recurrent Meningioma | unknown | N/A | 15 | Beijing Tiantan HospitalOTHER | 1 | Aug 10, 2021 | clinicaltrials |
| NCT04990271 | A Clinical Study on the Efficacy and Safety of VEC Intravenous Chemotherapy Combined With Conbercept Intravitreal Injection in the Treatment of Retinoblastoma | unknown | Phase 2 | 92 | Chengdu Kanghong Biotech Co., Ltd.INDUSTRY | 1 | Aug 4, 2021 | clinicaltrials |
| NCT04970615 | Educating Brain Tumor Patients Using Patient-specific Actual-size Three-dimensional Printed Models(IMAGE-3D) | unknown | — | 60 | Sümeyye SezerOTHER | 1 | Jul 21, 2021 | clinicaltrials |
| NCT04129710 | A Trial to Compare Ibrutinib Versus Lenalidomide in Combination With MRE-chemotherapy for Adult Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL) | unknown | Phase 2 | 120 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Jul 16, 2021 | clinicaltrials |
| NCT04856852 | Iodine-125 Brachytherapy Together With Chemotherapy in Patients With Newly Diagnosed Glioblastoma(IBCNG) | unknown | N/A | 84 | The Affiliated Hospital of Qingdao UniversityOTHER | 0 | Jun 29, 2021 | clinicaltrials |
| NCT04943718 | Personalized Vaccine for Patients With Recurrent Malignant Glioma | unknown | Phase 1 | 10 | Xuanwu Hospital, BeijingOTHER | 1 | Jun 29, 2021 | clinicaltrials |
| NCT04944069 | Almonertinib With Bevacizumab for EGFR-Mutant NSCLC Patients With Leptomeningeal Metastasis(ATTRACT) | unknown | N/A | 69 | Second Affiliated Hospital of Nanchang UniversityOTHER | 1 | Jun 29, 2021 | clinicaltrials |
| NCT04938297 | Rituximab,Zanubrutinib in Combination With Lenalidomide, Followed by Zanubrutinib or Lenalidomide Maintenance in Patients With Primary or Secondary CNS Lymphoma | unknown | Phase 2 | 100 | Henan Cancer HospitalOTHER_GOV | 1 | Jun 24, 2021 | clinicaltrials |
| NCT04902586 | Effect of Radiotherapy Concurrent of TTFields in Patients With Glioblastoma(ECTG001) | unknown | N/A | 30 | Zhongnan HospitalOTHER | 1 | May 26, 2021 | clinicaltrials |
| NCT04899427 | Phase II Study of Orelabrutinib Combined With PD-1 Inhibitor in Relapsed/Refractory Primary Central Nervous System Lymphoma | unknown | Phase 2 | 32 | Peking Union Medical College HospitalOTHER | 1 | May 24, 2021 | clinicaltrials |
| NCT04899453 | Intravitreal MTX and ZR Regimen in Newly Diagnosed PVRL | unknown | Phase 2 | 42 | Peking Union Medical College HospitalOTHER | 1 | May 24, 2021 | clinicaltrials |
Data updated 23 days agoSource updated Jul 7, 2022source: clinicaltrials